Literature DB >> 23660624

Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells.

S Munir1, G H Andersen, A Woetmann, N Ødum, J C Becker, M H Andersen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23660624     DOI： 10.1038/leu.2013.118

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  24 in total

1.  Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.

Authors:  S M Ahmad; S K Larsen; I M Svane; M H Andersen
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

2.  Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.

Authors:  Mads Hald Andersen
Journal:  J Natl Cancer Inst       Date:  2015-06-10       Impact factor: 13.506

Review 3.  Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology.

Authors:  Mads Hald Andersen
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

4.  PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine.

Authors:  Shamaila Munir Ahmad; Evelina Martinenaite; Morten Hansen; Niels Junker; Troels Holz Borch; Özcan Met; Marco Donia; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2016-07-01       Impact factor: 8.110

5.  The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Authors:  Shamaila Munir Ahmad; Evelina Martinenaite; Morten Holmström; Mia Aaboe Jørgensen; Özcan Met; Claudia Nastasi; Uffe Klausen; Marco Donia; Lars Møller Pedersen; Lars Munksgaard; Niels Ødum; Anders Woetmann; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-11-01       Impact factor: 8.110

6.  Spontaneous presence of FOXO3-specific T cells in cancer patients.

Authors:  Stine Kiaer Larsen; Shamaila Munir Ahmad; Manja Idorn; Özcan Met; Evelina Martinenaite; Inge Marie Svane; Per Thor Straten; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2014-11-14       Impact factor: 8.110

7.  Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response.

Authors:  Morten Orebo Holmström; Caroline Hasselbalch Riley; Vibe Skov; Inge Marie Svane; Hans Carl Hasselbalch; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2018-02-27       Impact factor: 8.110

8.  Frequent adaptive immune responses against arginase-1.

Authors:  Evelina Martinenaite; Rasmus Erik Johansson Mortensen; Morten Hansen; Morten Orebo Holmström; Shamaila Munir Ahmad; Nicolai Grønne Dahlager Jørgensen; Özcan Met; Marco Donia; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-12-26       Impact factor: 8.110

Review 9.  Anti-regulatory T cells.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2016-09-27       Impact factor: 9.623

10.  Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.

Authors:  C Krupka; P Kufer; R Kischel; G Zugmaier; F S Lichtenegger; T Köhnke; B Vick; I Jeremias; K H Metzeler; T Altmann; S Schneider; M Fiegl; K Spiekermann; P A Bauerle; W Hiddemann; G Riethmüller; M Subklewe
Journal:  Leukemia       Date:  2015-08-04       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.